TY  - JOUR
AU  - Jimenez-Fonseca, Paula
AU  - Carmona-Bayonas, Alberto
AU  - Martinez-Torron, Alba
AU  - Alsina, Maria
AU  - Custodio, Ana
AU  - Serra, Olbia
AU  - Cacho Lavin, Diego
AU  - Limón, María Luisa
AU  - Sauri, Tamara
AU  - López, Flora
AU  - Visa, Laura
AU  - Granja, Mónica
AU  - Martínez Lago, Nieves
AU  - Arrazubi, Virginia
AU  - Vidal Tocino, Rosario
AU  - Hernandez, Raquel
AU  - Aguado, Gema
AU  - Cano, Juana María
AU  - Martín Carnicero, Alfonso
AU  - Mangas, Monserrat
AU  - Pimentel, Paola
AU  - Fernández Montes, Ana
AU  - Macias Declara, Ismael
AU  - Longo, Federico
AU  - Ramchandani, Avinash
AU  - Martín Richard, Marta
AU  - Hurtado, Alicia
AU  - Azkarate, Aitor
AU  - Hernández Pérez, Carolina
AU  - Serrano, Raquel
AU  - Gallego, Javier
AU  - AGAMENON-SEOM study group
PY  - 2021
DO  - 10.1177/17588359211019672
SN  - 1758-8340
UR  - https://hdl.handle.net/10668/27514
T2  - Therapeutic advances in medical oncology
AB  - Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the lack of phase III...
LA  - en
KW  - HER2
KW  - chemotherapy
KW  - external validity
KW  - gastric cancer
KW  - oxaliplatin
KW  - trastuzumab
TI  - External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
TY  - research article
VL  - 13
ER  -